keyword
MENU ▼
Read by QxMD icon Read
search

Oncology, neuroblastoma

keyword
https://www.readbyqxmd.com/read/30082560/chylothorax-in-children-with-cancer-a-milky-predicament
#1
Sidharth Totadri, Amita Trehan, Anish Bhattacharya, Deepak Bansal, Savita Verma Attri, Radhika Srinivasan
Chylothorax is an uncommon complication in children. Although surgery and trauma are the most common causes encountered, hematological as well as solid malignancies can present with chylothorax. This study aimed to describe the presentation and management of malignant chylothorax in children. This is a case series from a pediatric hematology-oncology unit. Chylothorax was diagnosed by demonstrating high triglyceride content in the pleural fluid and a low cholesterol concentration in relation to the serum cholesterol...
October 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/30078040/staging-and-following-common-pediatric-malignancies-mri-versus-ct-versus-functional-imaging
#2
REVIEW
Stephan D Voss
Most pediatric malignancies require some form of cross-sectional imaging, either for staging or response assessment. The majority of these are solid tumors and this review addresses the role of MRI, as well as other cross-sectional and functional imaging techniques, for evaluating the most common pediatric solid tumors. The primary emphasis is on neuroblastoma, hepatoblastoma and Wilms tumor, three of the most common non-central-nervous-system (CNS) pediatric solid tumors encountered in young children. The initial focus will be a review of the imaging techniques and approaches used for diagnosis, staging and early post-treatment response assessment, followed by a discussion of the role surveillance imaging plays in pediatric oncology and a brief review of other emerging imaging techniques...
August 2018: Pediatric Radiology
https://www.readbyqxmd.com/read/30074458/endonasal-endoscopic-resection-of-olfactory-neuroblastoma-an-11-year-experience
#3
Gary L Gallia, Anthony O Asemota, Ari M Blitz, Andrew P Lane, Wayne Koch, Douglas D Reh, Masaru Ishii
OBJECTIVE Olfactory neuroblastoma (ONB) is a rare malignant neoplasm of the sinonasal cavity. Surgery has been and remains a mainstay of treatment for patients with this tumor. Open craniofacial resections have been the treatment of choice for many decades. More recently, experience has been growing with endoscopic approaches in the management of patients with ONB. The object of this study is to report the authors' experience over the past 11 years with ONB patients treated with purely endonasal endoscopic techniques...
August 3, 2018: Journal of Neurosurgery
https://www.readbyqxmd.com/read/30051358/the-potential-contribution-of-micrornas-in-anti-cancer-effects-of-aurora-kinase-inhibitor-azd1152-hqpa
#4
Ali Zekri, Yashar Mesbahi, Elham Boustanipour, Zahra Sadr, Seyed H Ghaffari
Neuroblastoma (NB) remains the critical challenge in pediatric oncology. It has the highest rate of spontaneous regression among all human cancers. Aurora kinase B (AURKB), a crucial regulator of malignant mitosis, is involved in chromosome segregation and cytokinesis. AZD1152-HQPA (Barasertib) is a small selective inhibitor of AURKB activity and currently bears clinical assessment for several malignancies. Studies suggested that microRNAs are involved in the pathobiology and chemoresistance of neuroblastoma...
July 26, 2018: Journal of Molecular Neuroscience: MN
https://www.readbyqxmd.com/read/30046297/corrigendum-a-comprehensive-safety-trial-of-chimeric-antibody-14-18-with-gm-csf-il-2-and-isotretinoin-in-high-risk-neuroblastoma-patients-following-myeloablative-therapy-children-s-oncology-group-study-anbl0931
#5
M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, Arlene Naranjo, Mitchell B Diccianni, Sheena C Tenney, Malcolm Smith, Karen S Messer, Robert Seeger, C Patrick Reynolds, L Mary Smith, Barry L Shulkin, Marguerite Parisi, John M Maris, Julie R Park, Paul M Sondel, Alice L Yu
[This corrects the article DOI: 10.3389/fimmu.2018.01355.].
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/30015396/risk-stratification-of-high-risk-metastatic-neuroblastoma-a-report-from-the-hr-nbl-1-siopen-study
#6
Daniel A Morgenstern, Ulrike Pötschger, Lucas Moreno, Vassilios Papadakis, Cormac Owens, Shifra Ash, Claudia Pasqualini, Roberto Luksch, Alberto Garaventa, Adela Canete, Martin Elliot, Aleksandra Wieczorek, Geneviève Laureys, Per Kogner, Josef Malis, Ellen Ruud, Maja Beck-Popovic, Gudrun Schleiermacher, Dominique Valteau-Couanet, Ruth Ladenstein
BACKGROUND: Risk stratification is crucial to treatment decision-making in neuroblastoma. This study aimed to explore factors present at diagnosis affecting outcome in patients aged ≥18 months with metastatic neuroblastoma and to develop a simple risk score for prognostication. PROCEDURE: Data were derived from the European high-risk neuroblastoma 1 (HR-NBL1)/International Society for Paediatric Oncology European Neuroblastoma (SIOPEN) trial with analysis restricted to patients aged ≥18 months with metastatic disease and treated prior to the introduction of immunotherapy...
July 17, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29995142/clinical-and-epidemiological-characteristics-and-survival-outcomes-of-children-with-neuroblastoma-21-years-of-experience-at-the-instituto-de-oncologia-pedi%C3%A3-trica-in-s%C3%A3-o-paulo-brazil
#7
Januária Nunes Lucena, Maria Teresa Seixas Alves, Simone Campos Vieira Abib, Gabriel Oliveira de Souza, Regina Pukenis de Castro Neves, Eliana Maria Monteiro Caran
OBJECTIVE: To describe the clinical and epidemiological characteristics and survival outcomes of children with neuroblastoma (NB) treated at a pediatric oncology center from 1991 to 2012. METHODS: A retrospective study with clinical and epidemiological data from 258 patients with neuroblastoma treated at a pediatric oncology center from 1991 to 2012, using medical records. RESULTS: The average age of the children at diagnosis was 40.5±46...
July 10, 2018: Revista Paulista de Pediatria: Orgão Oficial da Sociedade de Pediatria de São Paulo
https://www.readbyqxmd.com/read/29978962/-management-and-description-of-neonatal-tumours-in-a-surgical-oncology-unit
#8
J E Betancourth Alvarenga, F Vázquez Rueda, A Escassi Gil, J I Garrido Pérez, V Vargas Cruz, R M Paredes Esteban
AIM: Neonatal tumours represents less than 2% of all childhood cancers. The biological behaviour of this tumours will differ in older children. The tumours's biological differences and the immature physiological characteristics of newborns represent a great therapeutically challenge making newborns vulnerable. The aim of this study is to describe the clinical characteristics, associated malformations, diagnostic methods, treatment and the outcomes of neonatal tumours. METHODS: Retrospective review of patients ≤ 28 days-old with diagnosis of neonatal tumour between 2000-2016...
April 20, 2018: Cirugía Pediátrica: Organo Oficial de la Sociedad Española de Cirugía Pediátrica
https://www.readbyqxmd.com/read/29975402/different-infusion-durations-for-preventing-platinum-induced-hearing-loss-in-children-with-cancer
#9
REVIEW
Jorrit W van As, Henk van den Berg, Elvira C van Dalen
BACKGROUND: Platinum-based therapy, including cisplatin, carboplatin or oxaliplatin, or a combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one of the most important adverse effects is the occurrence of hearing loss or ototoxicity. In an effort to prevent this ototoxicity, different platinum infusion durations have been studied. This review is the second update of a previously published Cochrane review. OBJECTIVES: To assess the effects of different durations of platinum infusion to prevent hearing loss or tinnitus, or both, in children with cancer...
July 5, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29967609/a-comprehensive-safety-trial-of-chimeric-antibody-14-18-with-gm-csf-il-2-and-isotretinoin-in-high-risk-neuroblastoma-patients-following-myeloablative-therapy-children-s-oncology-group-study-anbl0931
#10
M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, Arlene Naranjo, Mitchell B Diccianni, Sheena C Tenney, Malcolm Smith, Karen S Messer, Robert Seeger, C Patrick Reynolds, L Mary Smith, Barry L Shulkin, Marguerite Parisi, John M Maris, Julie R Park, Paul M Sondel, Alice L Yu
Purpose: A phase 3 randomized study (COG ANBL0032) demonstrated significantly improved outcome by adding immunotherapy with ch14.18 antibody to isotretinoin as post-consolidation therapy for high-risk neuroblastoma (NB). This study, ANBL0931, was designed to collect FDA-required safety/toxicity data to support FDA registration of ch14.18. Experimental design: Newly diagnosed high-risk NB patients who achieved at least a partial response to induction therapy and received myeloablative consolidation with stem cell rescue were enrolled to receive six courses of isotretinoin with five concomitant cycles of ch14...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29881715/an-update-from-the-pediatric-proton-consortium-registry
#11
Clayton B Hess, Daniel J Indelicato, Arnold C Paulino, William F Hartsell, Christine E Hill-Kayser, Stephanie M Perkins, Anita Mahajan, Nadia N Laack, Ralph P Ermoian, Andrew L Chang, Suzanne L Wolden, Victor S Mangona, Young Kwok, John C Breneman, John P Perentesis, Sara L Gallotto, Elizabeth A Weyman, Benjamin V M Bajaj, Miranda P Lawell, Beow Y Yeap, Torunn I Yock
Background/objectives: The Pediatric Proton Consortium Registry (PPCR) was established to expedite proton outcomes research in the pediatric population requiring radiotherapy. Here, we introduce the PPCR as a resource to the oncology community and provide an overview of the data available for further study and collaboration. Design/methods: A multi-institutional registry of integrated clinical, dosimetric, radiographic, and patient-reported data for patients undergoing proton radiation therapy was conceived in May 2010...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29880247/development-and-current-use-of-in-hematopoietic-stem-cell-transplantation-in-children-and-adolescents-in-poland-report-of-the-polish-pediatric-study-group-for-hematopoietic-stem-cell-transplantation-of-the-polish-society-for-pediatric-oncology-and-hematology
#12
REVIEW
Jacek Wachowiak, Alicja Chybicka, Jerzy R Kowalczyk, Mariusz Wysocki, Jolanta Goździk, Ewa Gorczyńska, Krzysztof Kałwak, Jan Styczyński, Katarzyna Drabko, Anna Pieczonka
The purpose of the survey was to evaluate the development and current use of hematopoietic stem cell transplantation (HSCT) in Poland between 1989-2016. The data for analysis (indication, number of performed HSCT, HSCT type, donor type, and stem cell source, year) have been collected annually using a standardized form. In Poland, between 1989-2016, the number of pediatric transplant beds grew from one to 40 and number and rate of transplants increased annually from 1/year (0.8/10 million) to 186/year (248/10 million)...
May 16, 2018: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29546933/-pet-ct-technique-considerations-and-indications-in-the-oncology-study-of-pediatric-patients
#13
REVIEW
Andrés Retamal C, Giancarlo Schiappacasse F, Lizbet Pérez M, Pablo Alvayay Q, Isabel Schild W
Pediatric cancer is the second cause of death in children older than 5 years in our country, after trauma. Positron emission tomography/computed tomography (PET/CT) is a hybrid technique that involves radiation, which has been used for some time in adults and is being progressively imple mented in children. This technique allows morphological and functional assessments of the body with applications in neoplastic and non-neoplastic pathology. Its main role in oncology is in the evaluation and control of lymphomas, sarcomas and neuroblastomas, among others...
December 2017: Revista Chilena de Pediatría
https://www.readbyqxmd.com/read/29533873/discovery-of-meta-sulfamoyl-n-hydroxybenzamides-as-hdac8-selective-inhibitors
#14
Chunlong Zhao, Jie Zang, Qin'ge Ding, Elizabeth S Inks, Wenfang Xu, C James Chou, Yingjie Zhang
In the past decade, although research and development of histone deacetylase (HDAC) inhibitors as therapeutic agents have achieved great accomplishments, especially in oncology field, there is still an urgent need for the discovery of isoform-selective HDAC inhibitors considering the side effects caused by nonselective HDAC inhibitors. HDAC8, a unique class I zinc-dependent HDAC, is becoming a potential target in cancer and other diseases. In the current study, a novel series of N-hydroxy-3-sulfamoylbenzamide-based HDAC8 selective inhibitors (12a-12p) were designed and synthesized, among which compounds 12a, 12b and 12c exhibited potent HDAC8 inhibition with two-digit nanomolar IC50 values, and considerable selectivity over HDAC2 (>180-fold) and HDAC6 (∼30-fold) which was confirmed by western blot analysis...
April 25, 2018: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/29491100/a-retrospective-multicenter-study-of-carbon-ion-radiotherapy-for-locally-advanced-olfactory-neuroblastomas
#15
MULTICENTER STUDY
Hiroaki Suefuji, Masashi Koto, Yusuke Demizu, Jun-Ichi Saitoh, Yoshiyuki Shioyama, Hiroshi Tsuji, Tomoaki Okimoto, Tatsuya Ohno, Kenji Nemoto, Takashi Nakano, Tadashi Kamada
The purpose was to evaluate efficacy and safety of carbon ion radiotherapy (C-ion RT) in patients with locally advanced olfactory neuroblastomas (ONBs). This study was a sub-analysis of the Japan Carbon-Ion Radiation Oncology Study Group Study (1402 HN, UMIN000024473). Clinical data of T4 ONBs treated with C-ion RT at four Institutions between November 2003 and December 2014 were retrospectively reviewed. Twenty-one patients underwent C-ion RT. Seven patients had T4a and 14 had T4b tumours without cervical node metastases...
March 2018: Anticancer Research
https://www.readbyqxmd.com/read/29464082/myc-family-protein-overexpression-and-prominent-nucleolar-formation-represent-prognostic-indicators-and-potential-therapeutic-targets-for-aggressive-high-mki-neuroblastomas-a-report-from-the-children-s-oncology-group
#16
Risa Niemas-Teshiba, Ryosuke Matsuno, Larry L Wang, Xao X Tang, Bill Chiu, Jasmine Zeki, Jeannine Coburn, Kimberly Ornell, Arlene Naranjo, Collin Van Ryn, Wendy B London, Michael D Hogarty, Julie M Gastier-Foster, A Thomas Look, Julie R Park, John M Maris, Susan L Cohn, Robert C Seeger, Shahab Asgharzadeh, Naohiko Ikegaki, Hiroyuki Shimada
Neuroblastomas with a high mitosis-karyorrhexis index (High-MKI) are often associated with MYCN amplification, MYCN protein overexpression and adverse clinical outcome. However, the prognostic effect of MYC-family protein expression on these neuroblastomas is less understood, especially when MYCN is not amplified. To address this, MYCN and MYC protein expression in High-MKI cases (120 MYCN amplified and 121 non- MYCN amplified) was examined by immunohistochemistry. The majority (101) of MYCN -amplified High-MKI tumors were MYCN(+), leaving one MYC(+), 2 both(+), and 16 both(-)/(+/-), whereas non- MYCN -amplified cases appeared heterogeneous, including 7 MYCN(+), 36 MYC(+), 3 both(+), and 75 both(-)/(+/-) tumors...
January 19, 2018: Oncotarget
https://www.readbyqxmd.com/read/29435166/acquired-resistance-to-tyrosine-kinase-inhibitors-may-be-linked-with-the-decreased-sensitivity-to-x-ray-irradiation
#17
Maxim Sorokin, Roman Kholodenko, Anna Grekhova, Maria Suntsova, Margarita Pustovalova, Natalia Vorobyeva, Irina Kholodenko, Galina Malakhova, Andrew Garazha, Artem Nedoluzhko, Raif Vasilov, Elena Poddubskaya, Olga Kovalchuk, Leila Adamyan, Vladimir Prassolov, Daria Allina, Denis Kuzmin, Kirill Ignatev, Andreyan Osipov, Anton Buzdin
Acquired resistance to chemotherapy and radiation therapy is one of the major obstacles decreasing efficiency of treatment of the oncologic diseases. In this study, on the two cell lines (ovarian carcinoma SKOV-3 and neuroblastoma NGP-127), we modeled acquired resistance to five target anticancer drugs. The cells were grown on gradually increasing concentrations of the clinically relevant tyrosine kinase inhibitors (TKIs) Sorafenib, Pazopanib and Sunitinib, and rapalogs Everolimus and Temsirolimus, for 20 weeks...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29390274/a-highly-malignant-case-of-neuroblastoma-with-substantial-increase-of-single-nucleotide-variants-and-normal-mismatch-repair-system-a-case-report
#18
Lin-Qing Yuan, Jin-Hu Wang, Kun Zhu, Min Yang, Wei-Zhong Gu, Can Lai, Hao-Min Li, Qiang Shu, Xi Chen
RATIONALE: Neuroblastoma is a common abdominal malignancy in children. The chemoresistant and relapsed cases have poor prognosis. The genetic background and the mechanism of resistance remain unelucidated. Next-generation sequence (NGS) is becoming a popular tool to unravel the genetic background and to guide precision medicine in oncology studies as well as in clinical practice. PATIENT CONCERNS: Here we report a neuroblastoma case of a boy aged 2 years and 8 months when first diagnosed, with multiple metastatic sites found in both lungs...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29385676/naturally-occurring-canine-melanoma-as-a-predictive-comparative-oncology-model-for-human-mucosal-and-other-triple-wild-type-melanomas
#19
REVIEW
Belen Hernandez, Hibret A Adissu, Bih-Rong Wei, Helen T Michael, Glenn Merlino, R Mark Simpson
Melanoma remains mostly an untreatable fatal disease despite advances in decoding cancer genomics and developing new therapeutic modalities. Progress in patient care would benefit from additional predictive models germane for human disease mechanisms, tumor heterogeneity, and therapeutic responses. Toward this aim, this review documents comparative aspects of human and naturally occurring canine melanomas. Clinical presentation, pathology, therapies, and genetic alterations are highlighted in the context of current basic and translational research in comparative oncology...
January 30, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29376112/intravenous-immunoglobulin-with-prednisone-and-risk-adapted-chemotherapy-for-children-with-opsoclonus-myoclonus-ataxia-syndrome-associated-with-neuroblastoma-anbl00p3-a-randomised-open-label-phase-3-trial
#20
Pedro A de Alarcon, Katherine K Matthay, Wendy B London, Arlene Naranjo, Sheena C Tenney, Jessica A Panzer, Michael D Hogarty, Julie R Park, John M Maris, Susan L Cohn
Purpose: No previous clinical trial has been conducted for patients with neuroblastoma associated opsoclonus myoclonus ataxia syndrome (OMA), and current treatment is based on case reports. To evaluate the OMA response to prednisone and risk-adapted chemotherapy and determine if the addition of intravenous gammaglobulin (IVIG) further improves response, the Children's Oncology Group designed a randomized therapeutic trial. Patient and Methods: Eligible subjects were randomized to receive twelve cycles of IVIG (IVIG+) or no IVIG (NO-IVIG) in addition to prednisone and neuroblastoma risk-adapted chemotherapy...
January 2018: Lancet Child & Adolescent Health
keyword
keyword
171574
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"